nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

Merger and Formation:
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, a new biotechnology company focused on advancing genetic medicines135.

Financing:
The merger is backed by $75 million in financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, with participation from other top-tier investors135.

Leadership:
Jeff Walsh, formerly of bluebird bio, will serve as CEO of nChroma Bio, and Jeff Marrazzo, co-founder of Spark Therapeutics, will serve as Chairman of the Board135.

Technology Integration:
nChroma Bio combines Chroma’s expertise in epigenetic editing with Nvelop’s next-generation, non-viral in vivo delivery technologies to address key limitations in genetic medicine135.

Lead Program:
The company’s lead program, CRMA-1001, aims to treat chronic hepatitis B and D using a novel, non-cutting mechanism of gene silencing, with plans to enter clinical trials in 2025 and patient dosing in 202635.

Pipeline Expansion:
The funding will support the expansion of the delivery platform and the development of a pipeline of next-generation therapies targeting various tissues beyond the liver35.

Sources:

1. https://innovation.ucsf.edu/news/chroma-medicine-and-nvelop-therapeutics-unite-form-nchroma-bio-securing-75-million-accelerate

3. https://www.biopharmatrend.com/post/1065-chroma-medicine-and-nvelop-therapeutics-merge-to-form-nchroma-bio-with-75-million-financing/

5. https://www.biopharma-reporter.com/Article/2024/12/12/nchroma-bio-formed-by-merging-genetic-medicine-companies/